Side Effects and Monitor

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/121

encourage image

There's no tags or description

Looks like no tags are added yet.

122 Terms

1
New cards

tamoxifen

VTE, hot flashes endometrial cancer, cataracts

2
New cards

aromatase inhibitor

arthralgia, myalgia, bone loss, fracture risk, lipid effects

3
New cards

kadcyla (ado-trastuzumab)

thrombocytopenia, transaminitis, tbili elevation, neuropathy, cardiac monitoring

4
New cards

neratinib

breast

diarrhea → use ppx antidiarrheal

5
New cards

capecitabine

hand-foot syndrome, diarrhea, mucositis

take with food

6
New cards

olaparib

breast, prostate, ovarian(BRCA-mutated (usually HRD+); BRCA wild-type, HRD+ WITH BEV); BRCA1/2

anemia, neutropenia, fatigue, nausea, rare MDS/AML, pneumonitis, scr increase; CYP3A4 substrate

7
New cards

alpelisib

PIK3CA, breast

hyperglycemia, rash diarrhea. frequent and early glucose monitoring. can consider ppx nonsedating antihistamine

8
New cards

inavolisib

PIK3CA, breast

hyperglycemia, diarrhea, stomatitis, neutropenia

9
New cards

elacestrant

ESR1, breast

nausea, fatgue, arthtralgia

10
New cards

capivaserib

PTEN, breast

rash, diarrhea

11
New cards

everolimus

stomatitis → can use dex mouthwash

pneumonitis

12
New cards

trastuzumab dexrutecan (enhertu)

ILD/pneumonitis, nausea, myelosuppression

13
New cards

datopotamab dexrucan

breast

severe neutropenia, diarrhea

14
New cards

palbociclib

breast, CDK4/6

neutropenia, CBC monitoring

15
New cards

ribociclib

breast, CDK4/6

neutropenia, QT prolongation, hepatotoxicity, ECG, electrolytes, CBC, LFT monitoring

16
New cards

abemaciclib

breast, CDK4/6

diarrhea, less neutropenia that other CDK4/6 I, VTE, hepatotoxicity

17
New cards

AML defining cytogenesis

t(8;21), inv(16/t(16;16), t(15;17)

18
New cards

Ph+ALL

philadelphia positive; t(9;22)/BCR::ABL1. Hyper-CVAD+imatinib/dasatinib/ponatinib

19
New cards

asparginase

pancreatis, thrombosis, intracranial hemorrhage, hypofigrinogenemia, TG increase, hyperglycemia, hepatotoxicity

20
New cards

blina

CRS, ICANS; CD19

21
New cards

inotuzumab

VOS/SOS; CD22

22
New cards

gemtuzumab

VOD/SOS, hepatotoxicity, infusion reactions, myelosuppression

23
New cards

FLT3 inhibitors

QTc and CYP interactions; quizartinib → major QT considerations

24
New cards

IDH/menin inhibitors

differential syndrome: fever, edema/wt gain, pulmonary infiltrates/hypoxia, hypotension, renal dysfunction

25
New cards

PML::RARA t (15;17)

APL

26
New cards

del(5q)

use lenalidomide in MDS

27
New cards

BTK inhibitor

CLL

class SE: afib, bleeding, hypertension, infection

ibrutinib: diarrhea, arthralgia, drug interaction. Most risk for afib. not preferred due to toxicity

acalabrutinib: HA, cytopenia. less afib than ibrutinib

zanubrutinib: neutropenia. more neutropenia but better PFS and safety outcomes compared to ibrutnib

pirtobrutinib: bibcivalent. infection, bleeding, neutropenia

28
New cards

venetoclax

CLL

TLS, neutropenia, infection, CYP3A/P-gp interactions

29
New cards

Mosunetuzumab

Follicular lymphoma after 2 lines; CD20xCD3 T cell engager

Step up dosing

Bbw: CRS, neurological toxicity, fatigue, rash, pyrexia, cytopenia

30
New cards
31
New cards

obinutuzumab

CLL

infusion reaction, neutropenia, infection, HBV reactivation risk

32
New cards

PI3K inhibitor

immune-mediated colitis, hepatotoxicity, pneumonitis, infection, opportunistic infection concerns

33
New cards

imatinib

CML, ALL. first gen

SE: edema, muscle cramps, nausea, diarrhea, rash myelosuppression, hepatotoxicity

not preferred for intermediate/high risk CML

34
New cards

dasatinib

CML, ALL. second gen

SE: pleural effusion, pulmonary arterial hypertension, plt dysfunction/bleeding, myelosuppression

avoid taking with PPI

crosses blood brain barrier

35
New cards

nilotinib

CML. second gen

arterial occlusive events, hyperglycemia, hyperlipidemia, pancreatitis, QT prolongation

administer fasting. metabolic/cardiovascular monitoring

CML F317L

36
New cards

bosutinib

CML, ALL. second gen

diarrhea, nausea, hepatotoxicity, myelosuppression, renal function changed

CML F317L

37
New cards

ponatinib

CML. second gen

,hypertension, pancreatitis, hepatotoxicity, thrombosis

reserves for resistant disease/T315I with risk-adapted dosing. CML F317L

38
New cards

asciminib

CML, T315I

myelosuppression, hypertension, pancreatic enzyme elevation/pancreatitis, cardiovascular toxicity,

39
New cards

apalutamide

prostate

rash, fracture/falls, fatigue, hypothyroidism, HTN, seizure

strong CYP induction

40
New cards

darolutamide

prostate

lower CNS penetration → fewer CNS effects/DDIs

600mg bid with food

41
New cards

enzalutamide

prostate

fatigue, falls/fracture, HTN, seizure

strong CYP3A4 induction

42
New cards

abiraterone

prostate (only for mets CSPC)

always give with prednisone

mineralocorcicoid excess: HTN, hypokalemia, edema

hepatotoxicity

CYP3a4 substrate

43
New cards

mitoxanthrone

prostate

myelosuppression, cardiotoxicity

44
New cards

cabazitaxel

prostate

severe neutropenia, FN, diarrhea, neuropathy

45
New cards

lupron, goserelin, triptorelin

gnRH/LHRH agonist; ADT

46
New cards

erdafitinib

bladder, billiary tract FGFR1,2,3,4

hyperphosphatemia, ocular toxicity

47
New cards

lenvatinib

renal, liver, endometrial; VEGFR TKI “similar to bev”

hypertension, hypothyroidism, diarrhea, fatigue, proteinuria, rash, immune AE, HFS

48
New cards

axitinib

renal; VEGFR TKI

hypertension, transaminitis, HFS, immune AE

metabolized by CYP3A4

49
New cards

cabozatinib

renal; VEGFR TKI

shows intracranial response

diarrhea, hypothyroidism, transaminitis, rash, hypertension, HFS

50
New cards

cetuximab/panitumumab

colon; EGFR

rash, hypomagnesemia

51
New cards

Lu-177 PSMA-617

prostate

PSMA-positive mCRPC.

52
New cards

sorafenib

liver

HFS, diarrhea, rash, hypertension, fatigue; reduce start dose for hepatic/renal dysfunction

53
New cards

FGFR

cholangio

futibatinib, pemigatinibm erdafitinib

SE: hyperphophatemia, derm (HFS, alopecia, pronychia, dry skin, xerotomia, stomatitis

ocular toxicity

54
New cards

pralsetinib

RET; cholangio

55
New cards

KRAS or NRAS mutation in CRC

lacks benefit from cetuximab or panitumumab

56
New cards

HER2 in CRC

resistance to EGFR antibodies

57
New cards

BRCA½ or PALB2 in pancreas

favor platinum

58
New cards

selpercatinib

RET; pancreas

59
New cards

HRD+ in ovarian

platinum and PARPi sensitivity

60
New cards

niraparib

ovarian, BRCA wild-type, HRD+; BRCA-mutated (usually HRD+); maintenance; PARPi

thrombocytopenia, neutropenia, mds/aml, HTN, palpitation

200mg qd is wt <77kg or BL plt<150k; otherwise 300mg

61
New cards

tisotumab

tissue factor directed ADT; recurrent/met cervical Ca

ocular toxicity, bleeding, neuropathy

62
New cards

slim crab

MM

crab: at least 1qualifying

c: hypercalcemia; corrected calcium>11.5

r: renal; scr>2, crcl<40N

a: anemia; hgb<10 or 2< less than lln

b: bone lesion


s: bone marrow plasma cell>60

li: involved:uninvolved light chain ratio >100

mri: more than 1 focal lesion


63
New cards

MM high risk

del (17p)/tp53, t(4;14), t(14;16), t(14;20), gain/amp 1q and del(1p)

high beta-2 microglobulin with normal renal function, high plasma-cell s phase, plasma cell leukemia, extramedullary disease

64
New cards

erlotinib

pancreas

SE: rash

65
New cards

pralsetinib

RET; cholangiocarcinoma

66
New cards

BRAFV600E in CRC

encorafenib+antiEGFR+chemo

67
New cards

BRAFV600E in pancreas

dabrafenib/trametinib

68
New cards

pemigatinib

FGFR inhibitor

cholangiocarcinoma

69
New cards

regorafenib

CRC

dosing: 80mg→120mg→160mg

SE: HFS, hypertension, hepatotoxicity

70
New cards

zolbetuximab

gastric cancer/CLDN18.2

SE: N/V; PDL-1>1%

71
New cards

agnotistic - MSI-H/dMMR; TMB-H>10

pembro

72
New cards

agnotistic dMMR

dostarlimab

73
New cards

agnotistic - NTRK fusion

larotrectinib, entrectinib, repotrectenib

74
New cards

agnotistic - BRAFV600E

dabrafenib+trametinib (CRC EXCEPTION - ecorafenib+cetuximab)

75
New cards

agnotistic - RET fusion

selpercatinib (CAT RAT)

76
New cards

HER2 IHC 3+

enhertu

77
New cards

lonsurf

CRC, GEJ

severe neutropenia

78
New cards

rucaparib

ovarian BRCA wild-type, HRD+; BRCA-mutated (usually HRD+); PARPi

AST/ALT, cholesterol and SCr elevation, CYP interaction

79
New cards

PARPi class SE

anemia, thrombocytopenia/neutropenia, fatigue, nausea, GI, rare MDS/AML

80
New cards

mirvetuximab

overian; Fralpha

6mg/kg adjusted bw q21d

ocular, neuropathy, Gi toxicity, cytopenia

81
New cards

tacrolimus

GVHD ppx

nephrotoxicity, creatinine, hepatice, electrolyte. can increase blood pressure

CYP3A4

target level 5-20

82
New cards

Letermovir+tacrolimus

letemovir=CMV ppx

Letermovir inhibits CYP3A4, increase tacrolimus concentration

83
New cards

Azole/Aprepitant/letermovir+tacrolimus/cyclosporine/sirolimus/rutolitinib

Aprepitant/azole/letermovir CYP3a4 inhibitor. Increaes other drugs concentration

84
New cards
85
New cards
86
New cards

busulfan

HSCT conditioning

SE: seizures (ppx: keppra, ativan), SOS/VOD

AUc dosing, high emetogenic, avoid tylenol

87
New cards

cyclophosphamide

hemorrhagic cystitis, cardiotoxicity

88
New cards

mycophenolate

gvhd

gi toxicity

89
New cards

ruxolitinib

chronic/acute gvhd tx, ppx

cytopenia, infection

90
New cards

defibrotide

severe sos/vod

bleeding

91
New cards

ursodiol

sos/vod ppx

92
New cards

belumosudil

chronic gvhd tx

rock2 (beluga’s head looks like a rock)

93
New cards

axatinib

chronic gvhd tx

csf-1r

94
New cards

acute gvhd what organs?

skin, liver, gi

95
New cards

BRCA1/2 cancers

breast, ovarian, prostate, pancrease

96
New cards

Lynch syndrome cancers

CRC, small bowel, gastric, endometrial, ovarian, pancreas, biliary, urolithial

97
New cards

Li Fraumeni syndrome cancer

TP53

soft tissue sarcoma, osteosarcoma, breast, leukemia, brain, adernocortical carcinoma

98
New cards

osimertinib

lung; EGFR TKI

CNS penetration and activity against EGFR exon 19 deletion, L858R, and T790M

QT prolongation, cardiomyopathy, and interstitial lung disease.

99
New cards

alectinib

lung; ALK inhibitor

good CNS activity

CPK elevation, hepatotoxicity, bradycardia

100
New cards

brigatinib

lung; ALK inhibitor

Early pulmonary events, hypertension, CPK elevation